Prevalence of ovarian cancer among women with a CA125 level of 35 U/ml or less

Gynecologic and Obstetric Investigation

Volumn 65, Issue 2, 2008, Pages 133-138

  Kobayashi, Hiroshi ^a   Yamada, Yoshihiko ^a   Sado, Toshiyuki ^a   Sakata, Mariko ^a   Yoshida, Shozo ^a   Kawaguchi, Ryuji ^a   Kanayama, Seiji ^a   Shigetomi, Hiroshi ^a   Haruta, Shoji ^a   Tsuji, Yoriko ^a   Ueda, Sachiyo ^a   Kitanaka, Takashi ^a   Oi, Hidekazu ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

CA125; Ovarian cancer, prevalence; Screening, ovarian cancer

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PREVALENCE; PRIORITY JOURNAL; TRANSVAGINAL ECHOGRAPHY;

AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CHINA; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PREVALENCE; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY;

EID: 40349108790     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110014     Document Type: Article

References (18)

1. Szucs TD, Wyss P, Dedes KJ: Cost-effectiveness studies in ovarian cancer. Int J Gynecol Cancer 2003;13(suppl 2):212-219.
2. Kabawat SE, Bast RC Jr, Bhan AK, Welch WR, Knapp RC, Colvin RB: Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 1983;2:275-285.
3. von Schlippe M, Rustin GJ: Circulating tumour markers in ovarian tumours. Forum (Genova) 2000;10:383-392.
4. Verheijen RH, von Mensdorff-Pouilly S, van Kamp GJ, Kenemans P: CA 125: fundamental and clinical aspects. Semin Cancer Biol 1999;9:117-124.
5. Kobayashi H, Sumimoto K, Moniwa N, Imai M, Takakura K, Kuromaki T, Morioka E, Arisawa K, Terao T: Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan. Int J Gynecol Cancer 2007;17:37-43.
6. O'Rourke J, Mahon SM: A comprehensive look at the early detection of ovarian cancer. Clin J Oncol Nurs 2003;7:41-47.
7. Lewis S, Menon U: Screening for ovarian cancer. Expert Rev Anticancer Ther 2003;3:55-62.
8. Menon U, Jacobs IJ: Recent developments in ovarian cancer screening. Curr Opin Obstet Gynecol 2000;12:39-42.
9. Jacobs IJ, Menon U: Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004;3:355-366.
10. Anderiesz C, Quinn MA: Screening for ovarian cancer. Med J Aust 2003;178:655-656.
11. Markman M: Limitations to the use of the CA-125 antigen level in ovarian cancer. Curr Oncol Rep 2003;5:263-264.
12. Vuento MH, Stenman UH, Pirhonen JP, Makinen JI, Laippala PJ, Salmi TA: Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer. Gynecol Oncol 1997;64:141-146.
13. Milojkovic M, Hrgovic Z, Hrgovic I, Jonat W, Maass N, Bukovic D: Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis. Arch Gynecol Obstet 2004;269:176-180.
14. Asif N, Sattar A, Dawood MM, Rafi T, Aamir M, Anwar M: Pre-operative evaluation of ovarian mass: risk of malignancy index. J Coll Physicians Surg Pak 2004;14:128-131.
15. Rosenthal AN, Jacobs IJ: The role of CA 125 in screening for ovarian cancer. Int J Biol Markers 1998;13:216-220.
16. Mancuso A, De Vivo A, Triolo O, Irato S: The role of transvaginal ultrasonography and serum CA 125 assay combined with age and hormonal state in the differential diagnosis of pelvic masses. Eur J Gynaecol Oncol 2004;25:207-210.
17. Gohagan JK, Prorok PC, Hayes RB, Kramer BS: The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 2000;21(suppl):251S-272S.
18. McIntosh MW, Urban N, Karlan B: Generating longitudinal screening algorithms using novel biomarkers for disease. Cancer Epidemiol Biomarkers Prev 2002;11:159-166.